ライフサイエンスコーパス: docetaxel

1 29 to doxorubicin and 128 to gemcitabine and docetaxel).

2 irradiation or chemotherapy (gemcitabine or docetaxel).

3 umetinib + docetaxel; 254 received placebo + docetaxel).

4 .9% with ganetespib and docetaxel v 25% with docetaxel).

5 ilarly in mice in the presence or absence of docetaxel.

6 pared with 5% (3-7) in patients treated with docetaxel.

7 prostate cancer cells that were resistant to docetaxel.

8 ab or placebo in addition to trastuzumab and docetaxel.

9 eceived a relative dose intensity >= 85% for docetaxel.

10 t prostate cancer (mCRPC) and synergism with docetaxel.

11 tumor cell proliferation compared with free docetaxel.

12 tant prostate cancer previously treated with docetaxel.

13 nib + docetaxel and 256 to receive placebo + docetaxel.

14 ab and 425 patients were assigned to receive docetaxel.

15 atients received second-line nintedanib plus docetaxel.

16 xicity compared with equimolar doses of free docetaxel.

17 QR, 2.3-7.3; 95% CI, 2.8-5.6) with placebo + docetaxel.

18 line plus paclitaxel, and anthracycline plus docetaxel.

19 espib and docetaxel and 337 were assigned to docetaxel.

20 d cell survival and increased sensitivity to docetaxel.

21 , showed effective intracellular delivery of docetaxel.

22 0.71) for nivolumab and 0.80 (0.61-1.04) for docetaxel.

23 s, especially among those treated with early docetaxel.

24 de (600 mg/m(2)) followed by three cycles of docetaxel (100 mg/m(2); EC-D).

25 higher were more frequent with selumetinib + docetaxel (169 adverse events [67%] for selumetinib + do

26 ezolizumab (90 [15%] of 609 patients) versus docetaxel (247 [43%] of 578 patients).

27 pleted the study (251 received selumetinib + docetaxel; 254 received placebo + docetaxel).

28 nts received vinorelbine, 343 (23%) received docetaxel, 283 (19%) received gemcitabine, and 497 (33%)

29 rexate (40-60 mg/m(2) of body surface area), docetaxel (30-40 mg/m(2)), or cetuximab (250 mg/m(2) aft

30 in versus those who received gemcitabine and docetaxel (46.3% [95% CI 37.5-54.6] vs 46.4% [37.5-54.8]

31 kg volume equivalent followed by intravenous docetaxel 75 mg/m(2) (60 mg/m(2) in Korea, Taiwan, and J

32 (2) (C20) or 25 mg/m(2) (C25) is superior to docetaxel 75 mg/m(2) (D75) in terms of OS in patients wi

33 erapy (intravenous pemetrexed 500 mg/m(2) or docetaxel 75 mg/m(2) [investigator choice], every 21 day

34 ously receive either atezolizumab 1200 mg or docetaxel 75 mg/m(2) every 3 weeks by permuted block ran

35 physician's choice of a taxane (intravenous docetaxel 75 mg/m(2) every 3 weeks or intravenous paclit

36 nce per week for 6 weeks then 1 week off; or docetaxel 75 mg/m(2) for at least 60 min every 3 weeks),

37 All patients received docetaxel 75 mg/m(2) intravenously with 5 mg of predniso

38 ganetespib 150 mg/m(2) on days 1 and 15 with docetaxel 75 mg/m(2) on day 1 of a 21-day cycle or to do

39 675 mg/m(2) on days 1 and 8 and intravenous docetaxel 75 mg/m(2) on day 8 every 3 weeks.

40 e web response system to receive intravenous docetaxel 75 mg/m(2) plus either intravenous ramucirumab

41 arboplatin, and trastuzumab plus pertuzumab (docetaxel 75 mg/m(2); carboplatin area under the concent

42 oadjuvant CHT with androgen deprivation plus docetaxel (75 mg/m(2) body surface area every 3 weeks fo

43 1:1 to nivolumab (3 mg/kg every 2 weeks) or docetaxel (75 mg/m(2) every 3 weeks).

44 Patients received up to ten 21-day cycles of docetaxel (75 mg/m(2) intravenous, day 1) and prednisolo

45 cycles 2-8) in conjunction with neoadjuvant docetaxel (75 mg/m(2) on day 1 of cycles 1-4) and FEC (f

46 of vinorelbine (30 mg/m(2) on days 1 and 8), docetaxel (75 mg/m(2) on day 1), gemcitabine (1200 mg/m(

47 e randomly assigned to receive six cycles of docetaxel (75 mg/m(2)) and cyclophosphamide (600 mg/m(2)

48 nd extensive prior treatment including prior docetaxel (84%), cabazitaxel (48%), and abiraterone and/

49 d extensive prior treatment, including prior docetaxel (84%), cabazitaxel (48%), and abiraterone or e

50 ata available for analysis; g differentiated docetaxel (a US Food and Drug Administration-approved th

51 Interestingly, docetaxel, a common therapy for advanced PCa, further pr

52 ave a predictive impact on chemotherapy with docetaxel, a widely used drug in patients with metastati

53 trial highlights a differential response to docetaxel according to BMI, which calls for a body compo

54 ne-sensitive prostate cancer irrespective of docetaxel administration.

55 esistant prostate cancer cells and tumors to docetaxel, allowing a four-fold reduction in effective d

56 (MEK) inhibitor selumetinib + docetaxel with docetaxel alone as a second-line therapy for advanced KR

57 espib did not improve outcomes compared with docetaxel alone for any secondary end point, including s

58 rove progression-free survival compared with docetaxel alone.

59 75 mg/m(2) on day 1 of a 21-day cycle or to docetaxel alone.

60 associated with longer overall survival than docetaxel among patients with previously treated non-sma

61 e response rate was 20.1% with selumetinib + docetaxel and 13.7% with placebo + docetaxel (difference

62 ile range [IQR], 1.5-5.9) with selumetinib + docetaxel and 2.8 months (IQR, 1.4-5.5) with placebo + d

63 randomized 1:1; 254 to receive selumetinib + docetaxel and 256 to receive placebo + docetaxel.

64 335 were randomly assigned to ganetespib and docetaxel and 337 were assigned to docetaxel.

65 1.7-4.8; 95% CI, 2.7-4.1) with selumetinib + docetaxel and 4.5 months (IQR, 2.3-7.3; 95% CI, 2.8-5.6)

66 .7 months (IQR, 3.6-16.8) with selumetinib + docetaxel and 7.9 months (IQR, 3.8-20.1) with placebo +

67 ratio, patients who had previously received docetaxel and an androgen-signaling-targeted inhibitor (

68 The combination therapy of docetaxel and C3 receptor antagonist disrupted the mtDNA

69 Docetaxel and cabazitaxel improve overall survival compa

70 and some of their constituents interact with docetaxel and cabazitaxel on CRPC cells in culture and i

71 The microtubule-binding taxanes, docetaxel and cabazitaxel, are administered intravenousl

72 )F-FDG PET to assess response to combination docetaxel and carboplatin therapy in a co-clinical trial

73 acid) (PLGA) core and lipid layer containing docetaxel and clinically used inhibitor of sphingosine k

74 Purpose Docetaxel and cyclophosphamide (TC) was superior to doxo

75 ne-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the routine trea

76 tate cancer who were previously treated with docetaxel and had progression within 12 months while rec

77 Two breast cancer drugs, docetaxel and HER2-targeted lapatinib, were delivered to

78 ns indicate rapid emergence of resistance to docetaxel and increased sensitivity to carboplatin, ther

79 tivity (compared with administration of free docetaxel and non-targeted nanotherapeutic controls) in

80 VENICE trial, and 470 patients treated with docetaxel and placebo in the ENTHUSE 33 trial.

81 nd custirsen group (n=501) compared with the docetaxel and prednisone alone group (n=499) were neutro

82 nd custirsen group and 24 (5%) deaths in the docetaxel and prednisone alone group.

83 ination, compared with patients treated with docetaxel and prednisone alone.

84 el, prednisone, and custirsen combination or docetaxel and prednisone alone.

85 and custirsen and 181 (36%) of 499 receiving docetaxel and prednisone alone.

86 Sphere, comprising 476 patients treated with docetaxel and prednisone from the ASCENT2 trial, 526 pat

87 the effect of custirsen in combination with docetaxel and prednisone on overall survival in patients

88 ETATION: Addition of custirsen to first-line docetaxel and prednisone was reasonably well tolerated,

89 nisone, and custirsen and 512 were allocated docetaxel and prednisone.

90 nd custirsen vs 22.0 months [19.5-24.0] with docetaxel and prednisone; hazard ratio [HR] 0.93, 95% CI

91 rative cytostatic effect in combination with docetaxel and prevents adaptation and cell cycle re-entr

92 N, and KRAS gene mutations were treated with docetaxel and radiation.

93 tant prostate cancer previously treated with docetaxel and the alternative androgen signalling-target

94 cancer who had been previously treated with docetaxel and the alternative androgen-signaling-targete

95 atient-derived xenografts (PDX) sensitive to docetaxel and their counterparts that developed resistan

96 phamide), followed by 3 cycles of concurrent docetaxel and trastuzumab, followed by maintenance trast

97 s frequent and correlates with resistance to docetaxel and worst clinical outcomes in patients treate

98 interventions (prednisone, mitoxantrone, and docetaxel) and off-treatment data when on-study treatmen

99 subanalysis; 358 were treated with ADT plus docetaxel, and 361 were treated with ADT alone.

100 itant chemoradiation therapy with cisplatin, docetaxel, and 45Gy.

101 vity to three chemotherapy drugs: cisplatin, docetaxel, and doxorubicin.

102 therapy (40 [34%] to pemetrexed, 73 [63%] to docetaxel, and three [3%] discontinued before receiving

103 e events were lower with nivolumab than with docetaxel (any grade, 68% v 88%; grade 3 to 4, 10% v 55%

104 cluding paclitaxel and the second-generation docetaxel are currently limited by severe adverse effect

105 10.5 months (95% CI, 8.6 to 12.2 months) in docetaxel arm (hazard ratio [HR], 1.11; 95% CI, 0.899 to

106 spib and docetaxel arm and 4.3 months in the docetaxel arm (HR, 1.16; 95% CI, 0.96 to 1.403; P = .119

107 urvival was 4.2 months in the ganetespib and docetaxel arm and 4.3 months in the docetaxel arm (HR, 1

108 I, 9.0 to 12.3 months) in the ganetespib and docetaxel arm compared with 10.5 months (95% CI, 8.6 to

109 /kg loading dose and 6 mg/kg thereafter; and docetaxel at 75 mg/m(2), escalating to 100 mg/m(2) if to

110 data to investigate whether the efficacy of docetaxel-based chemotherapy differs from non-docetaxel-

111 ocetaxel-based chemotherapy differs from non-docetaxel-based chemotherapy in patients with breast can

112 (CHT) with androgen-deprivation therapy plus docetaxel before RP would improve biochemical progressio

113 cancer cells more migratory and resistant to docetaxel, cabazitaxel, and cisplatin chemotherapy.

114 linically relevant anticancer drug payloads (docetaxel, cabazitaxel, and gemcitabine) were successful

115 ne, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T hav

116 A second random assignment (R-C) compared docetaxel-capecitabine with an anthracycline-based regim

117 mide, paclitaxel, and trastuzumab (ACTH) and docetaxel, carboplatin, and trastuzumab (TCH).

118 g loading dose, 420 mg maintenance doses) or docetaxel, carboplatin, and trastuzumab plus pertuzumab

119 group and 123 (55.7%) of 221 patients in the docetaxel, carboplatin, and trastuzumab plus pertuzumab

120 tuzumab emtansine plus pertuzumab (n=223) or docetaxel, carboplatin, and trastuzumab plus pertuzumab

121 most common grade 3-4 adverse events in the docetaxel, carboplatin, and trastuzumab plus pertuzumab

122 [1%] of 223 patients vs 11 [5%] of 219 with docetaxel, carboplatin, and trastuzumab plus pertuzumab)

123 emotherapy plus dual HER2-targeted blockade (docetaxel, carboplatin, and trastuzumab plus pertuzumab)

124 treatment, compared with patients receiving docetaxel, carboplatin, and trastuzumab plus pertuzumab,

125 her trastuzumab emtansine plus pertuzumab or docetaxel, carboplatin, and trastuzumab plus pertuzumab.

126 of FDG-PET to assess response to combination docetaxel/carboplatin therapy in a co-clinical trial inv

127 itivity to carboplatin, therefore sequential docetaxel/carboplatin treatment could improve survival i

128 se who had received previous treatments with docetaxel, CD137 agonists, anti-CTLA4, or therapies targ

129 a new molecular mechanism of prostate cancer docetaxel chemoresistance mediated by the mammalian targ

130 We hypothesized that docetaxel chemotherapy (CT) could improve overall surviv

131 These findings suggest that continuation of docetaxel chemotherapy contributes to the survival benef

132 -resistant prostate cancer progressing after docetaxel chemotherapy.

133 and 25 patients, respectively, in the three docetaxel comparator groups).

134 The trial suggests that docetaxel CT may be an option to be discussed with selec

135 combination, patients on DPL received fewer docetaxel cycles (median, 6) vs 8 cycles in the control

136 To investigate whether the number of docetaxel cycles administered to patients deriving clini

137 arms, we investigated whether the number of docetaxel cycles administered to patients deriving clini

138 Total number of docetaxel cycles delivered as an independent factor for

139 s, patients who received a greater number of docetaxel cycles had superior OS; patients who received

140 The optimal total number of docetaxel cycles in patients with metastatic castration

141 n which g was used as the endpoint, compared docetaxel data with mitoxantrone data and showed that sm

142 Cabazitaxel and docetaxel demonstrated different toxicity profiles, with

143 blockade of pertuzumab and trastuzumab, with docetaxel, demonstrating an 8-year landmark overall surv

144 y patients who would benefit from concurrent docetaxel, demonstrating the feasibility and potential v

145 cell lung cancer, addition of selumetinib to docetaxel did not improve progression-free survival comp

146 The addition of ganetespib to docetaxel did not result in improved survival for salvag

147 nd 7.9 months (IQR, 3.8-20.1) with placebo + docetaxel (difference, 0.9 months; HR, 1.05 [95% CI, 0.8

148 and 2.8 months (IQR, 1.4-5.5) with placebo + docetaxel (difference, 1.1 months; hazard ratio [HR], 0.

149 metinib + docetaxel and 13.7% with placebo + docetaxel (difference, 6.4%; odds ratio, 1.61 [95% CI, 1

150 el vs 115 adverse events [45%] for placebo + docetaxel; difference, 22%).

151 ogy Research (USOR) 06-090 compared TC6 with docetaxel, doxorubicin, and cyclophosphamide (TAC6).

152 One mutation with a docetaxel drug-resistant effect was a truncated form of

153 Docetaxel drug-target engagement was assessed by confoca

154 Docetaxel (DTX) has been used as a standard chemotherapy

155 s) at low concentrations in conjunction with docetaxel (DTX) to overcome drug resistance of triple ne

156 strate a new oral route treatment regimen of docetaxel (DTX) without apparent toxicity.

157 Here, we developed docetaxel (DTX)-loaded micellar-like nanoparticles (MLNP

158 resistance against the chemotherapeutic drug docetaxel due to MCL1 upregulation but remain sensitive

159 a zeta potential of -20 mV, and exhibit high docetaxel encapsulation efficiency.

160 Celecoxib in addition to docetaxel enhanced cell viability in PTGS2-low cell line

161 Capecitabine administration with docetaxel, epirubicin, and cyclophosphamide did not prol

162 urthermore, mice treated with alphavbeta3-MP-docetaxel exhibited a significant decrease in bone-resid

163 of 126 patients who received gemcitabine and docetaxel), febrile neutropenia (26 [20%] and 15 [12%]),

164 nts in patients who received gemcitabine and docetaxel, fever (18 [12%] and 19 [15%]), and neutropeni

165 f fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) followed by surgery and 4 postoperative

166 About half received 3 cycles of docetaxel followed by 3 cycles of cyclophosphamide, epir

167 ed induction chemotherapy with cisplatin and docetaxel, followed by concomitant chemoradiation therap

168 Fifty-three men treated with docetaxel for mCRPC were tested for somatic BRCA1/2 muta

169 ious localised disease treatment or previous docetaxel for metastatic castration-sensitive prostate c

170 and those who received 4 or fewer cycles of docetaxel for other reasons, minimizing the effect of co

171 o to first-line therapy with trastuzumab and docetaxel for patients with locally recurrent, unresecta

172 evaluated the combination of ganetespib and docetaxel for second-line therapy of patients with advan

173 tion with taxane chemotherapy (paclitaxel or docetaxel) for 24 weeks.

174 0.27) for nivolumab and 0.43 (0.29-0.65) for docetaxel; for stable disease versus progressive disease

175 Continuous wave laser-induced release of docetaxel from a nanoshell-based DNA host complex showed

176 No patient in either docetaxel group had an ongoing response.

177 2 in the atezolizumab group and n=110 in the docetaxel group) or non-squamous (0.73 [0.60-0.89]; n=31

178 nce in DFS or OS according to BMI in the non-docetaxel group, while reduced DFS and OS were observed

179 p and 80 (63%) of 128 in the gemcitabine and docetaxel group.

180 observed with increasing BMI category in the docetaxel group.

181 piratory tract infection was reported in the docetaxel group.

182 therapy groups, 7.7 months (6.7-9.2) for the docetaxel groups, and 10.8 months (9.4-12.3) for the ant

183 therapy groups, 2.7 months (1.9-2.9) for the docetaxel groups, and 3.0 months (2.7-3.9) for the anti-

184 1 and VEGF expression, while low dose (5 nM) docetaxel had no significant effect.

185 de mice, RAD001 alone or in combination with docetaxel has suppressed tumour growth, VEGF expression

186 atezolizumab vs 10.3 months [8.8-12.0] with docetaxel; HR 0.74 [95% CI 0.58-0.93]; p=0.0102).

187 -risk nonmetastatic prostate cancer, CT with docetaxel improved OS from 89% to 93% at 4 years, with i

188 of C3a receptor sensitized PCa epithelia to docetaxel in a synergistic manner.

189 greater antitumor activity than 10 mg/kg of docetaxel in A549 non-small cell lung, as well as MDA-MB

190 A2 mutation showed a response rate of 25% to docetaxel in comparison to 71.1% in men with wildtype BR

191 and docetaxel with placebo, trastuzumab, and docetaxel in patients with HER2-positive metastatic brea

192 onger overall survival with nivolumab versus docetaxel in patients with previously treated advanced n

193 h nivolumab and/or ipilimumab, everolimus or docetaxel in phase 3 clinical trials, revealing the impo

194 evant improvement of overall survival versus docetaxel in previously treated non-small-cell lung canc

195 favorable tolerability profile compared with docetaxel in previously treated patients with advanced N

196 We assessed its efficacy and safety versus docetaxel in previously treated patients with non-small-

197 e of the prodrug, reduced exposure of active docetaxel in the circulation (compared with administrati

198 disease, and three (5.4%) of 56 responded to docetaxel in the second line of therapy.

199 c-Myc and NF-kappaB enhanced the efficacy of docetaxel in tumor xenografts.

200 or, prolonged overall survival compared with docetaxel in two independent phase III studies in previo

201 us ifosfamide in MPNST; and gemcitabine plus docetaxel in UPS.

202 Comparisons of nivolumab versus docetaxel included all randomised patients from the phas

203 Adding docetaxel increased the likelihood of a lower PSA and im

204 The addition of docetaxel increased the likelihood of achieving a PSA </

205 s including simvastatin-induced myopathy and docetaxel-induced neutropenia.

206 /m(2), paclitaxel 175 mg/m(2), or 75 mg/m(2) docetaxel) intravenously every 3 weeks.

207 ch as methotrexate, doxorubicin, paclitaxel, docetaxel, irinotecan and its important metabolite 7-eth

208 Resistance to docetaxel is a key problem in current prostate and breas

209 une checkpoint inhibitor after chemotherapy, docetaxel is recommended; in patients with nonsquamous N

210 the best of our knowledge, ramucirumab plus docetaxel is the first regimen in a phase 3 study to sho

211 latinum-containing regimen of irinotecan and docetaxel (IT) differed according to ERCC1 levels.

212 a simple self-assembling process to prepare docetaxel-loaded hyaluronic acid (HA) nanocapsules by us

213 month PSA </= 0.2 ng/mL was more likely with docetaxel, low-volume disease, prior local therapy, and

214 mucirumab plus docetaxel versus placebo plus docetaxel (median 4.07 months [95% CI 2.96-4.47] vs 2.76

215 was improved with atezolizumab compared with docetaxel (median overall survival was 13.8 months [95%

216 ility to various anticancer drugs, including docetaxel (microtubule stabilizer), gemcitabine (nucleos

217 xty-three patients were randomly assigned to docetaxel (n = 41) or cabazitaxel (n = 22); 44.4% receiv

218 oved with atezolizumab (n=241) compared with docetaxel (n=222; median overall survival was 15.7 month

219 were randomly allocated to ramucirumab plus docetaxel (n=263) or placebo plus docetaxel (n=267) and

220 e randomly allocated either ramucirumab plus docetaxel (n=263) or placebo plus docetaxel (n=267).

221 rumab plus docetaxel (n=263) or placebo plus docetaxel (n=267) and comprised the intention-to-treat p

222 rumab plus docetaxel (n=263) or placebo plus docetaxel (n=267).

223 did not alter the tumor growth inhibition by docetaxel of xenografted 22Rv1 cells, ellagic acid has t

224 e per day over 2 weeks along with 15 mg/m(2) docetaxel once per week.

225 ies obtained 2 to 3 days after initiation of docetaxel or cabazitaxel in 2 patients with castration-r

226 tained 2 to 5 days after their first dose of docetaxel or cabazitaxel were processed to assess microt

227 thods Patients were randomly assigned 2:1 to docetaxel or cabazitaxel.

228 's choice of standard doses of methotrexate, docetaxel, or cetuximab intravenously (standard-of-care

229 ), while the other half received 3 cycles of docetaxel plus capecitabine followed by 3 cycles of cycl

230 ed the efficacy and safety of treatment with docetaxel plus either ramucirumab-a human IgG1 VEGFR-2 a

231 re treated in phase III clinical trials with docetaxel plus prednisone (DP) or a DP-containing regime

232 402 patients were assigned to receive docetaxel plus trastuzumab plus pertuzumab, and 406 pati

233 b, and 406 patients were assigned to receive docetaxel plus trastuzumab plus placebo.

234 on adverse events of grade 3 or worse in the docetaxel, prednisone and custirsen group (n=501) compar

235 he MAINSAIL trial, 598 patients treated with docetaxel, prednisone or prednisolone, and placebo in th

236 taxel, prednisone, and lenalidomide (DPL) or docetaxel, prednisone, and a placebo (DP).

237 d for 214 (43%) of 501 patients treated with docetaxel, prednisone, and custirsen and 181 (36%) of 49

238 lled to the trial, of whom 510 were assigned docetaxel, prednisone, and custirsen and 512 were alloca

239 andomly assigned 1:1 centrally to either the docetaxel, prednisone, and custirsen combination or doce

240 s were attributable to 23 (5%) deaths in the docetaxel, prednisone, and custirsen group and 24 (5%) d

241 Patients assigned docetaxel, prednisone, and custirsen received weekly dos

242 survival 23.4 months [95% CI 20.9-24.8] with docetaxel, prednisone, and custirsen vs 22.0 months [19.

243 study of 1059 patients with mCRPC receiving docetaxel, prednisone, and lenalidomide (DPL) or docetax

244 the ASCENT2 trial, 526 patients treated with docetaxel, prednisone, and placebo in the MAINSAIL trial

245 tic encapsulating a hydrolytically sensitive docetaxel prodrug and conjugated to an antibody specific

246 We synthesized both paclitaxel and docetaxel prodrugs to formulate as ephrin A2-targeted li

247 s in the risk of death with nivolumab versus docetaxel remained similar to those reported in the prim

248 fication is associated with the emergence of docetaxel resistance and carboplatin responsiveness in T

249 ntify mutations of key genes associated with docetaxel resistance in nine endometrial cancer cell lin

250 To investigate the genetic basis of docetaxel resistance in TNBC, exome sequencing was perfo

251 C3a signaling in tumor cells contributed to docetaxel resistance.

252 at GL significantly reduced the viability of docetaxel-resistant and patient-derived spheres.

253 nt efficacy and survival in both taxane- and docetaxel-resistant in vivo anticancer mouse efficacy mo

254 stem cell niche in patient-derived cells, in docetaxel-resistant spheres and in an in vitro model.

255 Cs derived from prostate cancer patients, on docetaxel-resistant spheres with stem cell characteristi

256 d chemoresistant PDX, but not in the matched docetaxel-sensitive PDX tumor.

257 lification was validated in a second pair of docetaxel-sensitive/resistant BRCA1-mutated PDXs and aft

258 ed the mtDNA/C3a paracrine loop and restored docetaxel sensitivity.

259 iopsies after treatment with leuprolide plus docetaxel showed extensive microtubule bundling as did b

260 nal follow-up supports that ramucirumab plus docetaxel significantly improves progression-free surviv

261 oshamide (C)(600) followed by four cycles of docetaxel (T)(100) or six cycles of T(75)C(600) (adminis

262 s in vitro due to uMUC1 downregulation after docetaxel therapy was paralleled by in vivo imaging stud

263 Finally, after discontinuation of docetaxel therapy, median tumour growth (g) increased by

264 CA2 mutation does not preclude a response to docetaxel, there is overall a significant correlation be

265 therapy, whereas it was only 0.3 QALMs when docetaxel + trastuzumab was used as a systemic therapy.

266 ced HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab or placebo, highe

267 wed a reduction in probe accumulation in the docetaxel treated group (n = 5, p < .05).

268 evident in PCa xenografts 2 to 3 days after docetaxel treatment but was decreased or lost with acqui

269 ng, disease progression following first-line docetaxel treatment established by radiographic evidence

270 tant BRCA1-mutated PDXs and after short-term docetaxel treatment in several TNBC/BRCA1-mutated PDXs a

271 nt prostate cancer that had progressed after docetaxel treatment with a Karnofsky performance status

272 son score at diagnosis, region, and previous docetaxel treatment.

273 nstitutes a major mechanism of resistance to docetaxel treatment.

274 -mutated breast cancer who had progressed on docetaxel treatment.

275 cabazitaxel versus mitoxantrone after prior docetaxel treatment.

276 e-fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial is a prospective, phase 2 trial of 252

277 hibitors should preferably be avoided during docetaxel use in patients with breast cancer who are und

278 s was neutropenia (30.9% with ganetespib and docetaxel v 25% with docetaxel).

279 This study compared gemcitabine and docetaxel versus doxorubicin as first-line treatment for

280 antly in patients allocated ramucirumab plus docetaxel versus placebo plus docetaxel (median 4.07 mon

281 l survival with pertuzumab, trastuzumab, and docetaxel versus placebo, trastuzumab, and docetaxel wer

282 (169 adverse events [67%] for selumetinib + docetaxel vs 115 adverse events [45%] for placebo + doce

283 n in the risk of death with nivolumab versus docetaxel was 28% (hazard ratio, 0.72; 95% CI, 0.62 to 0

284 Treatment with 8 or more cycles of docetaxel was associated with superior OS (hazard ratio

285 CA1/2 protein expression and the response to docetaxel was found.

286 uzumab were given until disease progression; docetaxel was given for six cycles, or longer at the inv

287 uent to response at 6 months on nivolumab or docetaxel was longer than after progressive disease at 6

288 biopsies 2 to 3 days after the first dose of docetaxel was markedly lower in 4 nonresponding patients

289 ial growth factor receptor 2 antagonist-plus docetaxel was previously reported to improve progression

290 or targeted delivery of the chemotherapeutic docetaxel, we showed that bone tumor burden could be red

291 overall survival rates with nivolumab versus docetaxel were 23% (95% CI, 16% to 30%) versus 8% (95% C

292 d docetaxel versus placebo, trastuzumab, and docetaxel were maintained after a median of more than 8

293 ety profiles of pertuzumab, trastuzumab, and docetaxel were maintained in the overall safety populati

294 -TGBF and GS-Wnt mice were more resistant to docetaxel, whereas organoids from the CIN tumors were mo

295 response compared with patients treated with docetaxel, which was associated with a long-term surviva

296 tosterone suppression, with or without early docetaxel, will improve survival in men with metastatic,

297 ring androgen-deprivation therapy (ADT) plus docetaxel with ADT alone for initial metastatic hormone-

298 kinase kinase (MEK) inhibitor selumetinib + docetaxel with docetaxel alone as a second-line therapy

299 epirubicin plus cyclophosphamide followed by docetaxel with or without celecoxib).

300 y and safety of pertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in pa